371 related articles for article (PubMed ID: 30671869)
1. Brexpiprazole: A Review in Schizophrenia.
Frampton JE
Drugs; 2019 Feb; 79(2):189-200. PubMed ID: 30671869
[TBL] [Abstract][Full Text] [Related]
2. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
McEvoy J; Citrome L
Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
[TBL] [Abstract][Full Text] [Related]
3. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
5. Brexpiprazole: A Review in Schizophrenia.
Garnock-Jones KP
CNS Drugs; 2016 Apr; 30(4):335-42. PubMed ID: 27023789
[TBL] [Abstract][Full Text] [Related]
6. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.
Citrome L; Ota A; Nagamizu K; Perry P; Weiller E; Baker RA
Int Clin Psychopharmacol; 2016 Jul; 31(4):192-201. PubMed ID: 26963842
[TBL] [Abstract][Full Text] [Related]
7. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
Hope J; Castle D; Keks NA
Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
[TBL] [Abstract][Full Text] [Related]
8. [Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI
Suzuki M; Niidome K; Maeda K; Kikuchi T; Usami T; Futamura T
Nihon Yakurigaku Zasshi; 2019; 154(5):275-287. PubMed ID: 31735758
[TBL] [Abstract][Full Text] [Related]
9. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis.
Kishi T; Ikuta T; Matsuda Y; Sakuma K; Iwata N
Psychopharmacology (Berl); 2020 May; 237(5):1459-1470. PubMed ID: 32002559
[TBL] [Abstract][Full Text] [Related]
11. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
Citrome L
Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
[TBL] [Abstract][Full Text] [Related]
12. Brexpiprazole: First Global Approval.
Greig SL
Drugs; 2015 Sep; 75(14):1687-97. PubMed ID: 26310190
[TBL] [Abstract][Full Text] [Related]
13. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
Citrome L
Int J Clin Pract; 2015 Nov; 69(11):1211-20. PubMed ID: 26477545
[No Abstract] [Full Text] [Related]
14. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies.
Correll CU; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Kane JM
Schizophr Res; 2016 Jul; 174(1-3):82-92. PubMed ID: 27157799
[TBL] [Abstract][Full Text] [Related]
15. Brexpiprazole: A Partial Dopamine Agonist for the Treatment of Schizophrenia.
Ekinci A; Ekinci O
Rev Recent Clin Trials; 2018 Jan; 13(1):37-44. PubMed ID: 28828976
[TBL] [Abstract][Full Text] [Related]
16. Brexpiprazole.
Markovic M; Gallipani A; Patel KH; Maroney M
Ann Pharmacother; 2017 Apr; 51(4):315-322. PubMed ID: 28228056
[TBL] [Abstract][Full Text] [Related]
17. Brexpiprazole for the treatment of schizophrenia.
Yee A
Expert Rev Neurother; 2016; 16(2):109-22. PubMed ID: 26650624
[TBL] [Abstract][Full Text] [Related]
18. Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (Secondary Publication).
Ishigooka J; Usami T; Iwashita S; Kojima Y; Matsuo S
Neuropsychopharmacol Rep; 2020 Jun; 40(2):122-129. PubMed ID: 32297486
[TBL] [Abstract][Full Text] [Related]
19. Discovery research and development history of the dopamine D
Kikuchi T; Maeda K; Suzuki M; Hirose T; Futamura T; McQuade RD
Neuropsychopharmacol Rep; 2021 Jun; 41(2):134-143. PubMed ID: 33960741
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of brexpiprazole: comparison with aripiprazole.
Stahl SM
CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
